Literature DB >> 571211

Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man.

R Huwyler, W Born, E E Ohnhaus, J A Fischer.   

Abstract

The metabolism and the urinary excretion of synthetic human and salmon calcitonin-(1--32) [hCT-(1--32), sCT-(1--32)] administered by constant infusions for 240 min were investigated in eight normal subjects. On gel filtration of plasma obtained during the infusions mainly intact hCT-(1--32) and sCT-(1--32) were recognized with homologous radioimmunoassay systems. During constant infusions to equilibrium of 0.04 mg hCT-(1--32) and sCT-(1--32), the metabolic clearance rates (MCR) amounted to 8.4 +/- 1.1 and 3.1 +/- 0.1 ml/kg per min, respectively (P less than 0.01). When hCT-(1--32) was infused at rates of 1 and 4 mg/240 min, the MCR were lower than with 0.04 mg hCT-(1--32), but still higher than with 0.04 mg sCT-(1--32). The half-lives of disappearance of hCT-(1--32) were faster compared to sCT-(1--32), but the difference was not statistically significant. The urinary clearance of hCT-(1--32) determined during the 1 and 4 mg/240 min infusions of hCT-(1--32), as well as of sCT-(1--32) determined during the 0.04-mg infusions of sCT-(1--32) was about 0.1% of the MCR. The half-lives of disappearance of hCT- and sCT-(1--32) incubated in vitro in plasma and urine ranged from 17 to more than 72 h, and the degradation did not affect our calculations of the metabolic breakdown of exogenous CT in vivo.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 571211     DOI: 10.1152/ajpendo.1979.236.1.E15

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  15 in total

1.  Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin (sCT).

Authors:  P J Sinko; Y H Lee; V Makhey; G D Leesman; J P Sutyak; H Yu; B Perry; C L Smith; P Hu; E J Wagner; L M Falzone; L T McWhorter; J P Gilligan; W Stern
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Process analysis of fluidized bed granulation.

Authors:  J Rantanen; A Jørgensen; E Räsänen; P Luukkonen; S Airaksinen; J Raiman; K Hänninen; O Antikainen; J Yliruusi
Journal:  AAPS PharmSciTech       Date:  2001-10-17       Impact factor: 3.246

3.  A study of the antiresorptive activity of salmon calcitonin microspheres using cultured osteoclastic cells.

Authors:  Bhas A Dani; Adrian T Raiche; David A Puleo; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

4.  Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers.

Authors:  C Wüster; W Schurr; S Scharla; F Raue; H W Minne; R Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Availability of synthetic salmon calcitonin in tissue fluid after a single intravenous dose.

Authors:  E Concia; M Cruciani; F Bartucci; L Arrigoni; A Longoni
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Calcitonin: perspectives in current concepts.

Authors:  H J Wolfe
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

7.  Strategic approaches for enhancement of in vivo transbuccal peptide drug delivery in rabbits using iontophoresis and chemical enhancers.

Authors:  Dong-Ho Oh; Min-Ju Kim; Sang-Ok Jeon; Jo-Eun Seo; Seong-Hoon Jeong; Jeong-Won Kang; Young-Wook Choi; Sangkil Lee
Journal:  Pharm Res       Date:  2014-09-18       Impact factor: 4.200

8.  Calcitonin secretion rate in elderly normal subjects.

Authors:  M Pedrazzoni; G Ciotti; L Davoli; G Pioli; G Girasole; T Santini; M Michelini; P P Vescovi; M Passeri
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

9.  Effect of human calcitonin (hCT) on glucose- and arginine-stimulated insulin secretion.

Authors:  S Sgambato; N Passariello; G Paolisso; A Marano; R Buoninconti; P Tesauro
Journal:  Acta Diabetol Lat       Date:  1986 Jan-Mar

Review 10.  Clinical efficacy of salmon calcitonin in Paget's disease of bone.

Authors:  F R Singer
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.